. MediPharm Labs Ships Cannabis Topicals and Accelerates Development to Expand Topicals Presence in Medical and Adult-Use Markets
March 25, 2020 at 8:09 am
Published by NCV Newswire
BARRIE, Ontario, March 25, 2020 (GLOBE NEWSWIRE) â€” MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (â€śMediPharm Labsâ€ť or the â€śCompanyâ€ť) a global leader in specialized, research-driven pharmaceutical-qualityÂ cannabis extraction, distillation and derivative products, today announced it has completed its first shipment of bottled cannabis topicals under a contract manufacturing agreement. The Company also announced it is accelerating its research and development program to expand the Companyâ€™s presence in the growing Canadian, and future international, medical and adult-use topicals markets.
First Topical Shipments
Leveraging the Companyâ€™s 25,000 sq. ft. licensed space, the Company completed its first shipment of topicals from its GMP-certified Barrie facility this week including the filling and packaging on behalf of its customer. The topicals, shipped yesterday, will be distributed to final medical or adult-use purchasers directly by the customer.
Weâ€™re pleased to be working with our brand-name customers in the field of topicals, a key product category under legalization 2.0 and for MediPharm Labsâ€™ customers. We completed our first topical unit shipment direct to our customer earlier this week.
Pat McCutcheon, Chief Executive Officer, MediPharm Labs